Session » Health Services Research - Poster III
-
Abstract Number: 2227
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
-
Abstract Number: 2228
Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy
-
Abstract Number: 2229
Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
-
Abstract Number: 2230
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
-
Abstract Number: 2231
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
-
Abstract Number: 2232
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
-
Abstract Number: 2233
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
-
Abstract Number: 2234
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
-
Abstract Number: 2235
Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study
-
Abstract Number: 2236
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
-
Abstract Number: 2237
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
-
Abstract Number: 2238
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
-
Abstract Number: 2239
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
-
Abstract Number: 2240
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
-
Abstract Number: 2241
Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review
-
Abstract Number: 2242
Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
-
Abstract Number: 2243
The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines
-
Abstract Number: 2244
Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
-
Abstract Number: 2245
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
-
Abstract Number: 2246
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
-
Abstract Number: 2247
REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
-
Abstract Number: 2248
The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis
-
Abstract Number: 2249
Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
-
Abstract Number: 2250
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
-
Abstract Number: 2251
Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective
-
Abstract Number: 2252
Estimated Cost of SLE Hospitalizations
-
Abstract Number: 2253
Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France